CHICAGO--(BUSINESS WIRE)-- SIWA Therapeutics, Inc., a pre-clinical stage biopharmaceutical company focused on aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking, will participate in two September virtual conferences.

Lewis Gruber, CEO and CSO of SIWA, will attend Biopharm America 2020, which will take place virtually from September 21-24. Gruber also will attend the Oncology Virtual Partnering event hosted by BIO and Inova Software from September 22-24. Gruber will be available to meet one-on-one with potential new partners during both conferences to discuss exciting new developments in SIWA’s approach to treating both cancer and infectious diseases.

SIWA recently announced the results of a study demonstrating that 318H binds to both COVID-19 and Influenza A, thus showing promise for 318H to become a broad-spectrum antiviral drug. 318H also is being tested on bacterially-infected cells. Additionally, the company is actively partnering with a major institution in pancreatic cancer.

Investors are encouraged to request a meeting with SIWA Therapeutics through the respective scheduling portal on the conference’s website. Interested parties who are not attending either upcoming conference are encouraged to reach out via email at: partners@siwatherapeutics.com

About SIWA Therapeutics, Inc.

SIWA Therapeutics, Inc. is focused on treating aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking. SIWA’s proprietary humanized monoclonal antibody, 318H, selectively targets cells with an abnormally high level of glycolysis (the Warburg effect) and oxidative stress. Targeted cells include specifically cancer cells, senescent cells, and virally and bacterially-infected cells. 318H binds to cancer cells, senescent cells and cells infected by SARS-CoV-2 (COVID-19) and Influenza A; testing of bacterially-infected cells is in progress. We are partnering with a major institution in pancreatic cancer (a 318H in vivo PDX pancreatic cancer study in humanized mice is in process). Charles River Laboratories recently completed an in vivo 318H tolerability and pharmacokinetic studies in non-human primates in preparation for filing an IND application with the FDA. No adverse effects were observed.

More information is available at www.siwatherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005858/en/